KyungDong Pharm home
Prescription Medicines

Megarovan Soft Cap. 5/1000mg

Product Category
Dyslipidemia treatment
Active Ingredients
Rosuvastatin / Omega 3 fatty acids
Appearance
An oblong, white film-coated soft capsule containing a pale yellow oily substance.
Reimbursement Code
648104600
View Regulatory Information on the MFDS Portal ↗
1. Composition and Strength : 1 capsule
■ Active ingredients:
Omega-3-acid ethyl ester 90 (EP)............................................................1000,00mg
(460.0 mg as eicosapentaenoic acid (EPA) ethyl ester, 380 mg as docosahexaenoic acid (DHA) ethyl ester, and 4.0 mg alpha-tocopherol as an antioxidant)
Rosuvastatin Calcium (EP)… … … … … … … … … … … … … … … … … … … 5.20mg (5mg as rosuvastatin)
■ Additives (animal-derived ingredients): Gelatin (pork, leather)
■ Other additives: concentrated glycerin, magnesium oxide, triethyl citrate, aminomethacrylic acid copolymer, hypromellose

2. Effectiveness
Treatment of mixed type (IIb) dyslipidemia in which LDL-cholesterol levels are adequately controlled but triglyceride levels are not adequately controlled during rosuvastatin monotherapy in adult patients at high risk of coronary heart disease (CHD).

3. Dosage and dosage
Patients before and while taking this drug should eat a standard cholesterol-lowering diet and continue this during the treatment period.
This drug is administered only to adults. To avoid gastrointestinal disorders, take 2 to 4 capsules once a day with a meal (1,000 mg of omega-3-acid ethyl ester/5 mg of rosuvastatin per capsule).
Patients who are taking omega-3-acid ethyl ester and rosuvastatin in combination can switch to this drug (a combination drug with the same content of each active ingredient) for convenience of administration.

4. Precautions for use
1. Do not administer to the following patients.
1) Patients with hypersensitivity to the components of this drug
2) Patients with active liver disease, including persistent serum transaminase elevations of unknown cause or serum transaminase elevations exceeding 3 times the upper limit of normal.
3) Patients with myopathy
4) Patients taking cyclosporine concurrently
5) Patients with severe renal failure (creatinine clearance (CLcr) < 30mL/min)
6) Pregnant and lactating women, and women of childbearing potential who do not use appropriate contraception.
This drug should be administered to women of childbearing age only when there is a high possibility that they will not become pregnant and when they have been informed of the potential risk to the fetus.
7) Rosuvastatin at a dose of 40 mg is contraindicated in patients prone to myopathy/rhabdomyolysis. These factors are as follows.
- Moderate renal impairment (creatinine clearance < 60ml/min)
- Hypothyroidism
- If you have a history or family history of genetic muscle disease
- If there is a history of muscle toxicity to other HMG-CoA converting enzyme or fibrate drugs
- alcoholism
- Situations in which plasma concentrations may increase
- Asian patient
- Concomitant administration of fibrate-based drugs
8) Children under 18 years of age

2. Administer with caution to the following patients.
1) Like other HMG-CoA reductase inhibitors, rosuvastatin should be administered with caution to patients who consume excessive alcohol or have a history of liver disease. It is recommended that liver enzyme tests be performed repeatedly as clinically necessary before and after starting treatment with this drug. Patients with hypercholesterolemia secondary to hypothyroidism or nephrotic syndrome must treat the causative disease before taking this drug.
2) As with other HMG-CoA reductase inhibitors, effects on skeletal muscle, such as myalgia and myopathy, and rarely rhabdomyolysis, have been reported in patients receiving rosuvastatin. Immune-mediated necrotizing myopathy has been reported in patients taking or discontinuing statins, including rosuvastatin. Immune-mediated myopathy is clinically characterized by weakened proximal muscles and increased CK (creatine kinase) in the blood, and the symptoms persist even after discontinuation of treatment.
• As with other HMG-CoA reductase inhibitors, the risks and benefits of treatment should be considered in the following patients with factors predisposing to myopathy/rhabdomyolysis, and clinical monitoring is recommended. Treatment should not be started if the CK (creatine kinase) value is significantly increased from the baseline level (more than 5 times the upper limit of normal) before treatment.
- Patients with renal impairment
- Hypothyroidism
- If you have a history or family history of genetic muscle disease
- If there is a history of muscle toxicity to other HMG-CoA reductase inhibitors or fibrates.
- alcohol abuse
- Seniors over 70 years old
- Situations in which plasma concentrations may increase
- Concomitant administration of fibrate-based drugs
• During treatment, unexplained muscle pain, weakness or cramps should be reported immediately, especially if associated with malaise or fever. In these patients, the CK level should be measured, and if the CK level is significantly elevated (more than 5 times the upper limit of normal) or if the muscle symptoms are severe and cause daily discomfort even if the CK level increases below 5 times the upper limit of normal, administration of this drug should be discontinued. Once symptoms resolve and CK levels return to normal, consideration should be given to restarting this drug or another HMG-CoA reductase inhibitor at the lowest dose with close monitoring. Routine monitoring of CK levels is not necessary in asymptomatic patients.
• Do not measure CK after strenuous exercise or when there are other causes that may increase CK values, as it may make interpretation of the measurement results difficult. If the CK value increases significantly from baseline (more than 5 times the upper limit of normal), a confirmatory test should be performed within 5 to 7 days. Even when repeating the test, this drug should not be administered if the baseline CK value increases more than 5 times the upper limit of normal.
3) Administration of this drug should be discontinued in acute severe conditions that suggest worsening of myopathy or renal failure secondary to rhabdomyolysis (e.g. sepsis, hypotension, major surgery, wounds, severe metabolic/endocrine/electrolyte diseases, uncontrolled epileptic seizures).
4) In clinical trials, there was no evidence of increased effects on skeletal muscle in the small number of patients who received rosuvastatin in combination with other drugs. However, in the case of other HMG-CoA reductase inhibitors, the frequency of myositis and myopathy increased in patients receiving concurrent treatment with fibric acid derivatives (including gemfibrozil), cyclosporine, nicotinic acid, azole antifungals, protease inhibitors, and macrolide antibiotics.
Gemfibrozil increases the risk of myopathy when combined with HMG-CoA reductase inhibitors. Therefore, the combined use of this drug and gemfibrozil is not recommended. When administering this drug in combination with fibrates or niacin, the benefits and risks should be carefully evaluated. A dose of 40 milligrams of rosuvastatin is contraindicated when coadministered with fibrate-based drugs.
5) In patients taking high doses of rosuvastatin, especially 40mg, proteinuria, mostly of tubular origin, detected by dipstick test was observed. This is usually transient and is not a predictor of acute or progressive renal failure. Renal function tests should be considered during the follow-up period for patients receiving 40 mg.
6) According to a pharmacokinetic study of rosvastatin, an increase in systemic exposure (median AUC and Cmax approximately 2-fold increase) was observed in Asians compared to Caucasians, so this should be taken into consideration when determining dosage for Asians.
7) Patients at high risk of bleeding such as severe trauma or surgery
8) Patients with liver dysfunction
9) Patients with hypersensitivity or allergy to fish
10) Patients with severe muscle atony or ocular muscle atony (cases of recurrence when administered the same or different types of statin drugs have been reported)

3. Adverse reactions
1) Rosuvastatin/omega-3-acid ethyl ester complex
○ Clinical trial results
The safety of this drug was reviewed in a clinical trial in which this drug (test group) or rosuvastatin single agent (control group) was administered for 8 weeks to patients at high risk for coronary heart disease whose LDL-C was adequately controlled by rosuvastatin monotherapy but whose triglyceride levels were not adequately controlled.
(1) A total of 47 adverse reactions were reported in 35 patients during the entire clinical trial, and 22 adverse reactions were reported in a total of 16 patients (15.5%) in the test group (103 patients).
(2) Among the adverse reactions reported in the test group, there were 2 adverse reactions for which a causal relationship with this drug could not be ruled out: muscle pain was reported in 1 patient (0.97%), and facial paralysis was reported in 1 patient (0.97%).
(3) Regardless of the causal relationship with the drug, one or more adverse reactions reported in the test drug administration group are as follows.
- Infection: nasopharyngitis, periodontitis, upper respiratory tract infection
- Nervous system: facial paralysis, headache, parkinsonism
- Digestive system: Gastritis
- Skin and subcutaneous tissue system: erythema
- Musculoskeletal system: muscle pain, joint pain
- Ophthalmological system: increased tear secretion, presbyopia
- Malignant neoplasm: Ovarian cancer
- Abnormal clinical test values: increased ALT, increased AST, increased γ-GT
○ Domestic post-marketing survey results
As a result of a post-marketing survey conducted on 638 people over 6 years for re-examination in Korea, the occurrence rate of adverse events was reported to be 15.52% (99/638 people, 148 cases in total) regardless of causal relationship. Among these, no serious adverse drug reactions were reported for which a causal relationship could not be ruled out. In addition, unexpected adverse drug reactions for which a causal relationship cannot be ruled out are listed in the table below according to their frequency of occurrence.
(see table)
2) Additional information about each main ingredient of this drug
The information specified below is based on clinical trials and post-marketing experience with individual ingredients rosuvastatin and omega-3-acid ethyl ester.
○ Information collected from rosuvastatin
(1) Reported adverse reactions were generally mild and transient. Less than 4% of patients in the rosuvastatin treatment group discontinued the study due to adverse reactions.
The frequency of adverse reactions was classified as follows:
Common (>1/100, <1/10);
Uncommon (>1/1,000, <1/100);
Rare (>1/10,000, <1/1,000);
Very rare (<1/10,000).
Not known (cannot be estimated from available data)
(see table)
Note 1: In the JUPITER clinical trial, the most reported adverse reaction was in patients with fasting blood sugar levels of 5.6 to 6.9 mmol/L (reported by 2.8% in the rosuvastatin group and 2.3% in the placebo group).
As with other HMG-CoA reductase inhibitors, adverse reactions tended to increase as the dose increased.
(2) Effect on kidneys: Proteinuria, mostly of tubular origin, detected by dipstick test, was observed. The phenomenon of conversion of urine protein from negative or very small amounts to ++ or higher occurred in less than 1% of cases at 10 or 20 milligrams and in about 3% of cases at 40 milligrams. A slight increase in urine protein from negative or very small amounts to + was also observed at the 20 mg dose. Proteinuria decreased or disappeared spontaneously during treatment in most cases and is not a predictor of acute or progressive renal failure. Hematuria was observed in patients and clinical trial data administered rosuvastatin, but the frequency of occurrence was low.
(3) Effects on the musculoskeletal system: Effects on the musculoskeletal system with or without acute renal failure (e.g., myalgia, myopathy (including myositis), rarely rhabdomyolysis, etc.) have been reported in patients treated with all doses of rosuvastatin (especially 20 mg or more). In the patient group receiving rosuvastatin, creatinine kinase (CK) levels increased in a dose-dependent manner. In most cases, it was mild, asymptomatic, and transient. If creatinine kinase (CK) levels increase significantly (more than 5 times the upper normal limit), treatment should be temporarily discontinued.
(4) Effects on the liver: As with other HMG-CoA reductase inhibitors, transaminase levels increased in a dose-dependent manner in a small number of patients receiving rosuvastatin. In most cases, it was mild, asymptomatic, and transient.
(5) Overseas post-marketing experience
In addition to the above adverse reactions, the following adverse reactions were reported during post-marketing surveillance.
- Nervous system: Very rare polyneuropathy, amnesia, peripheral neuropathy (frequency unknown)
- Respiratory system and chest: cough, difficulty breathing (frequency unknown)
- Gastrointestinal system: Diarrhea (frequency unknown)
- Hematological disorders: Thrombocytopenia (frequency unknown)
- Hepatobiliary system: very rare, jaundice, hepatitis, rarely increased transaminases
- Skin and subcutaneous tissue disorders: Stevens-Johnson syndrome (frequency unknown), drug reaction syndrome with increased eosinophils and systemic symptoms (DRESS) (frequency unknown)
- Musculoskeletal system: Rarely lupus-like syndrome, muscle rupture, very rarely arthralgia, immune-mediated necrotizing myopathy (frequency unknown)
- Kidney: Very rare hematuria
- Other: Edema (frequency unknown)
The following adverse reactions have been reported in relation to some statin drugs.
- Mental nervous system: depression, sleep disorders (including insomnia and nightmares) (frequency unknown)
- Respiratory system: Exceptional cases such as interstitial lung disease, especially during long-term administration
- Urogenital system: sexual dysfunction, gynecomastia (frequency unknown)
- Hepatobiliary system: Fatal and non-fatal liver failure
There have been rare reports of post-marketing cognitive impairment associated with statin use. (e.g. memory loss, forgetfulness, amnesia, memory impairment, confusion) Such cognitive impairment has been reported with all statin drugs. These reports are generally not serious and reversible after discontinuation of drug use, but there is variation in the time of symptom onset (1 day to several years) and symptom improvement (median 3 weeks). The induction or worsening of severe muscle atony or ocular muscle atony has been reported with the administration of statin drugs.
(6) Domestic post-marketing survey results
As a result of a use result survey conducted on 3,081 people over 6 years for re-examination in Korea, the incidence of adverse events regardless of causal relationship was 10.06% (310 people, 415 cases), mainly headache 0.78% (24 people, 24 cases), dizziness 0.75% (23 people, 23 cases), and ALT increase 0.58% (18 people, 18 cases). 18 cases), chest pain, cough, and muscle pain were reported in 0.49% (15 people, 15 cases) each, and of these, 2.92% (90 people, 106 cases) of adverse drug reactions for which a causal relationship with rosuvastatin could not be ruled out.
The most common adverse drug reactions reported were ALT increase at 0.55% (17 people, 17 cases), muscle pain at 0.42% (13 people, 13 cases), headache at 0.39% (12 people, 12 cases), CK increase at 0.29% (9 people, 9 cases), dizziness at 0.26% (8 people, 8 cases), constipation, and AST increase. 0.16% (5 people, 5 cases), asthenia and joint pain each at 0.13% (4 people, 4 cases), fatigue and numbness at 0.10% each (3 people, 3 cases), paresthesia, chest discomfort, nausea, abdominal pain, diarrhea, loss of appetite, abdominal distension, itching, liver function test abnormalities at 0.06% each (2 people, 2 cases), syncope, systemic pain, Muscle cramps, gout, and erectile dysfunction each occurred in 0.03% (1 person, 1 case). Among these, muscle pain and joint pain in one patient were serious adverse drug reactions, and unexpected adverse drug reactions that did not appear before marketing included joint pain in 0.13% (4 patients, 4 cases), fatigue and numbness in 0.10% (3 patients, 3 cases), paresthesia, chest discomfort, loss of appetite, abdominal distension, and liver function test abnormalities in 0.06% (2 patients, 2 cases) respectively, syncope, and General pain, muscle cramps, gout, and erectile dysfunction occurred in 0.03% (1 person, 1 case) each, and one case of joint pain was reported as a serious and unexpected adverse drug reaction.
There were 98 adverse events voluntarily reported during the re-examination period, of which 2 cases of acute renal failure and 1 case each of oliguria, thrombocytopenia, and increased serum creatinine were reported as serious and unexpected adverse drug reactions.
○ Information collected from omega-3-acid ethyl ester
(1) Drug-related adverse reactions that occurred in more than 1% of patients in eight randomized, placebo-controlled, double-blind, parallel group clinical trials for hypertriglyceridemia are shown in [Table 1]. In clinical trials, 3.5% of patients administered omega-3-acid ethyl ester and 2.6% of patients administered placebo discontinued treatment due to adverse reactions.
See [Table 1]: Adverse reactions that occurred in placebo-controlled clinical trials in patients with hypertriglyceridemia

(2) Other adverse reactions observed during the clinical trial period
Adverse reactions observed in one or more patients in 22 clinical trials of hypertriglyceridemia are as follows.
• Whole body: abdominal distension, asthenia, body odor, chest pain, chills, suicide, fever, whole body edema, fungal infection, malaise, neck pain, tumor, rheumatoid arthritis, sudden death, viral infection.
• Cardiovascular system: arrhythmia, bypass surgery, cardiac arrest, hyperlipidemia, hypertension, migraine, myocardial infarction, myocardial ischemia, occlusion, peripheral vascular disorder, syncope, tachycardia.
• Digestive system: Anorexia, constipation, dry mouth, dysphagia, colitis, fecal incontinence, gastritis, gastroenteritis, gastrointestinal disorders, increased appetite, intestinal obstruction, melena, pancreatitis, gastroenteritis, vomiting, reflux or belching due to the smell or taste of fish, nausea, flatulence, diarrhea.
• Blood-lymphatic system: lymphadenopathy
• Metabolic and nutritional disorders: edema, hyperglycemia, increased ALT and AST
• Musculoskeletal system: arthralgia, arthritis, myalgia, pathological fractures, tendon disorders.
• Nervous system: Central nervous system tumor, depression, dizziness, emotional instability, facial paralysis, insomnia, vasodilatation, dizziness.
• Respiratory system: Asthma, bronchitis, frequent coughing, difficulty breathing, nosebleeds, laryngitis, pharyngitis, pneumonia, rhinitis, sinusitis.
• Skin: hair loss, eczema, itching, sweating
• Special senses: cataracts
• Urogenital system: cervical abnormalities, endometrial tumor, epididymitis, erectile dysfunction.
(3) Domestic post-marketing survey results
- As a result of a post-marketing use outcome survey conducted on 759 people over 6 years in Korea, the adverse reaction rate was 20.95% (159 people/759 people, 240 cases), of which the rate of adverse drug reactions for which a causal relationship with the drug cannot be ruled out was 3.95% (30 people/759 people, 37 cases), and indigestion was 0.79% (6 people/759 people, 37 cases). 6 cases), dizziness 0.40% (3 people/759 people, 3 cases), headache, constipation, nausea, gastrointestinal disorder, ALT increase, AST increase, itching (symptoms) 0.26% each (2 people/759 people, 2 cases), paresthesia, diarrhea, dry mouth, chest pain, chest discomfort, edema, fatigue, discomfort, weight loss, muscle pain, hyperlipidemia, Bronchitis, shortness of breath, and cough were each reported in 0.13% (1 person/759 people, 1 case). There were no serious adverse drug reactions.
- A total of 5 unexpected adverse drug reactions occurred, with one case each of paresthesia, chest discomfort, fatigue, discomfort, and weight loss. There were no serious adverse drug reactions.
(4) Others: Atrial fibrillation has been commonly reported. In overseas clinical trials, additional adverse reactions such as hypotension, gastrointestinal bleeding, and gout were occasionally reported (about 0.1% to 1%).
(5) In one clinical trial evaluating the efficacy and safety of the combined use of 4 capsules of 1000 mg of omega-3-acid ethyl ester and 1 tablet of 20 mg of atorvastatin (taken once a day for 8 weeks) in patients with combined type (type II b) of hypercholesterolemia and hypertriglyceridemia, the combined administration group of omega-3-acid ethyl ester and atorvastatin Adverse reactions observed in more than 1 out of 42 patients are as follows.
• Digestive system: constipation, upper abdominal discomfort, large intestine polyp, toothache
• Nervous system: headache, drowsiness, paresthesia, fainting
• Infections: nasopharyngitis, shingles
• Respiratory system: chronic obstructive pulmonary disease, runny nose
• Abnormalities in the entire body and administration site: sudden death
• Skin and subcutaneous tissue system: itching
• Musculoskeletal system: joint pain
• Genitourinary system: hematuria

4. General precautions
1) Treatment General
- Before administering this drug, laboratory tests should be performed to confirm that the patient's triglyceride level continues to be outside the normal range.
- Diseases that promote hypertriglyceridemia (hypothyroidism, diabetes) must be treated appropriately to improve serum triglyceride levels. Before considering drug therapy, medications known to worsen hypertriglyceridemia (beta-blockers, thiazide diuretics, estrogens, etc.) should be discontinued or changed if possible. Considering the main triggers of hypertriglyceridemia (overweight, excessive alcohol intake), appropriate diet and exercise should be combined, and in overweight patients, weight loss should be implemented.
- The use of lipid regulators can be considered only after sufficient trials have been made to obtain satisfactory results with non-drug therapy. Patients should be made aware that the use of lipid-modifying agents does not diminish the importance of diet adherence.
- During drug therapy with this drug, laboratory tests should be performed periodically to measure the patient's triglyceride level. For patients who do not show an adequate response even after 2 months of administration, treatment with this drug should be discontinued.
- In some patients, omega-3-acid ethyl ester increased low-density lipoprotein cholesterol (LDL-cholesterol) levels. As with other lipid regulators, LDL-cholesterol levels should be checked periodically while taking this drug.
- Omega-3-acid ethyl ester is not used for exogenous hypertriglyceridemia (type I hyperchylomicronemia), and experience with its use for secondary endogenous hypertriglyceridemia (especially in patients with uncontrolled diabetes) is limited.
2) Interstitial lung disease: Unusual cases such as interstitial lung disease have been reported with some statin drugs, especially during long-term administration. Presenting symptoms may include difficulty breathing, non-productive coughing and general deterioration of health (fatigue, weight loss and fever). If a patient is suspected of developing interstitial lung disease, statin drug treatment should be discontinued.
3) Post-marketing cases of fatal and non-fatal liver failure were rarely reported in patients taking statin drugs, including rosuvastatin, and an increase in liver levels was observed when omega-3-acid ethyl ester was administered. If severe liver damage and/or hyperbilirubinemia or jaundice with clinical symptoms occurs while taking this drug, treatment should be discontinued immediately. Do not re-administer this drug if no other etiology is found.
4) An increase in HbA1c and fasting blood sugar levels was reported when administering HMG-CoA reductase inhibitors, including rosuvastatin.
5) Diabetes: Some evidence suggests that hyperglycemia, which requires appropriate diabetes treatment, may occur in some patients at high risk of developing diabetes in the future. However, the vascular risk reduction effect of statins exceeds these risks and therefore cannot be a reason to discontinue statin treatment. Patients at risk (fasting blood sugar 5.6-6.9 mmol/L, BMI > 30kg/m2, elevated triglyceride level, hypertension) should undergo clinical and laboratory monitoring according to treatment guidelines.
In the JUPITER study, the total incidence of diabetes reported in patients with fasting blood sugar levels of 5.6 to 6.9 mmol/L was 2.8% in the rosuvastatin group and 2.3% in the placebo group.
6) Immune-mediated necrotizing myopathy: Immune-mediated necrotizing myopathy, an autoimmune myopathy related to statin use, has been reported. Immune-mediated necrotizing myopathy manifests as proximal muscle weakness and increases in blood CPK, and the symptoms persist even after discontinuation of statin administration. Additionally, muscle biopsy shows necrotizing myopathy without significant infection, and symptoms improve upon administration of immunosuppressants.
7) There is no experience of combined use of omega-3-acid ethyl ester and fibrate agents for hypertriglyceridemia.
8) INR monitoring is recommended when administering this drug in combination with anticoagulants and aspirin. (Refer to 6. Drug interactions)
- INR may increase when HMG-CoA reductase inhibitors are coadministered with warfarin.
- An increase in bleeding time was observed when omega-3-acid ethyl ester was used together with anticoagulants and acetylsalicylic acid. However, during the administration of omega-3-acid ethyl ester, the secretion of thromboxane A2 decreased, but no significant effects were observed on other coagulation factors. Some studies on omega-3-acid ethyl ester showed that bleeding time was prolonged, but the bleeding time reported in these studies did not exceed the normal range and there were no clinically significant cases.
9) Genetic polymorphism: SLCO1B1(OATP1B1) c compared to SLCO1B1 c.521TT and ABCG2 c.421CC. The genotype of 521CC or ABCG2 (BCRP) c.421AA has been reported to be associated with increased exposure (AUC) of rosuvastatin. Although the safety and effectiveness of this drug according to genetic polymorphisms have not been established, the dose needs to be adjusted according to the patient's treatment response and tolerance.
10) Severe skin adverse reactions: Severe skin adverse reactions that can be life-threatening or fatal, such as Stevens-Johnson syndrome (SJS), eosinophilia, and drug reaction syndrome with systemic symptoms (DRESS), have been reported with rosuvastatin. When prescribing, patients should be counseled and closely monitored for symptoms and signs of severe skin reactions. If symptoms and signs suggestive of these skin reactions occur, this medication should be discontinued immediately and alternative treatment options should be considered.
If a patient develops a severe reaction such as Stevens-Johnson syndrome or drug reaction syndrome with eosinophilia and systemic symptoms due to the use of this drug, treatment with this drug should not be resumed at any time.
11) In patients with cardiovascular disease or cardiovascular risk factors, a dose-dependent increase in the risk of atrial fibrillation was confirmed. The observed risk was highest at the 4 g/day dose. If atrial fibrillation occurs, treatment with this drug should be permanently discontinued.
12) Severe muscle asthenia and ocular muscle atony: Rarely, statin drugs may cause or worsen severe muscle asthenia or ocular muscle atony. This drug should be used with caution in patients with these conditions. Administration should be discontinued if severe muscle atony or ocular muscle atony occurs or worsens.

5. Drug interactions
No studies have been conducted on drug interactions between this drug and other medications. The following shows drug interactions for individual active ingredients of rosuvastatin and omega-3-acid ethyl ester.
1) Rosuvastatin
(1) Effects of other drugs on rosuvastatin
• In vitro and in vivo studies have shown that rosuvastatin does not interact clinically with cytochrome P450 (acting as a substrate, inhibitor or inducer).
• Rosuvastatin is a substrate for some transporter proteins, such as the liver uptake drug transporter OATP1B1 and the efflux transporter BCRP, and when inhibitors of these transporter proteins are used together with rosuvastatin, the blood concentration of rosuvastatin increases, which may increase the risk of myopathy.
(see table).

• Effects of other drugs
- Antacids: When rosuvastatin was co-administered with antacids containing aluminum hydroxide and magnesium hydroxide, the plasma concentration of rosuvastatin decreased by about 50%. However, this effect was alleviated when antacids were administered 2 hours after rosuvastatin. The clinical relevance of this interaction has not been studied.
- Fusidic acid: Interaction studies between rosuvastatin and fusidic acid have not been conducted. As with other statin drugs, muscle-related adverse reactions, including rhabdomyolysis, have been reported when rosuvastatin and fusidic acid were used together in post-marketing experience. Therefore, combined use of rosuvastatin and fusidic acid is not recommended. If possible, it is recommended to temporarily discontinue rosuvastatin administration, and if administration is unavoidable, close monitoring should be performed.
- Ticagrelor: Ticagrelor may affect the excretion of rosuvastatin through the kidneys, increasing the risk of rosuvastatin accumulation. In some cases, coadministration of ticagrelor and rosuvastatin resulted in decreased renal function, increased CPK levels, and rhabdomyolysis.
(2) Effects of rosuvastatin on other drugs
- Warfarin: When used in combination with rosuvastatin, warfarin has no significant effect on pharmacokinetics. However, like other HMG-CoA reductase inhibitors, coadministration of rosuvastatin and warfarin may increase the INR compared to administration of warfarin alone. INR monitoring is recommended when starting, stopping, or adjusting the dose of rosuvastatin in patients receiving vitamin K antagonists (e.g., warfarin).
- Cyclosporine: Co-administration of rosuvastatin and cyclosporine does not affect the blood concentration of cyclosporine.
- Fenofibrate/fibric acid derivatives: Pharmacokinetic interactions between fenofibrate and rosuvastatin were not observed, but pharmacokinetic interactions may occur. Gemfibrozil, fenofibrate, other fibrate-based drugs, and nicotinic acid in lipid-lowering doses (more than 1 g per day) can cause myopathy when administered alone, and therefore increase the risk of myopathy when administered in combination with HMG-CoA reductase inhibitors. When co-administering fibrate-type drugs, administration of 40 mg of rosuvastatin is contraindicated, and 5 mg should be administered as the initial dose.
- Oral contraceptives: When administered in combination with oral contraceptives, the AUC of ethinyl oestradiol and norgestrel increased by 26% and 34%, respectively. This increase in plasma concentration should be taken into consideration when selecting the dosage of oral contraceptives. Since there is no pharmacokinetic data for patients taking rosuvastatin and HRT together, a similar effect should not be ruled out. However, in clinical trials, the combination was administered frequently in women and the tolerability was excellent.
- Effects on other drugs: There was no clinically significant interaction with digoxin or ezetimibe.
2) Omega-3-acid ethyl ester
(1) Anticoagulants: When omega-3-acid ethyl ester was used together with anticoagulants and acetylsalicylic acid, an increase in bleeding time was observed. This may be the result of an additive effect on bleeding time, but no hemorrhagic complications have been recorded.
① Anticoagulant: When a patient receiving blood-thinning therapy uses omega-3 acid ethyl ester and an anticoagulant in combination, or when treatment with omega-3 acid ethyl ester is discontinued, the patient's prothrombin time (PT) and international normalized ratio (INR) values must be monitored.
② Acetylsalicylic acid: Patients should be aware of the potential for prolonged bleeding time.
(2) Cytochrome P450-dependent monooxygenase activity: Products containing omega-3-acid ethyl ester increase hepatic cytochrome P450 concentration and activity in rats. The potential of omega-3-acid ethyl esters to induce P450 activity in humans has not yet been studied.

6. Administration to pregnant and lactating women
1) Pregnant women
There have been no clinical trials conducted on this drug in pregnant women, so, like rosuvastatin, this drug should not be administered to pregnant women, and women who may become pregnant should use appropriate contraception.
(1) Rosuvastatin
The safety of rosuvastatin in pregnant and lactating women has not been established and should not be used during pregnancy or lactation.
Women of childbearing potential should use appropriate contraception. Because cholesterol and cholesterol biosynthesis products are essential for fetal development, the potential risks of inhibiting HMG-CoA reductase outweigh the benefits of treatment during pregnancy. There is evidence of limited reproductive toxicity in animal studies. If you become pregnant while using rosuvastatin, you should stop taking it immediately.
(2) Omega-3-acid ethyl ester
There are no clinical trials conducted in pregnant women. It is not known whether omega-3-acid ethyl ester causes fetal harm or affects fertility when administered to pregnant women. During pregnancy, it should be used only when the therapeutic benefits outweigh the risks to the fetus.
2) Nursing mothers
The safety of this drug for nursing mothers has not been established, so it should not be used during breastfeeding. There is no information on whether this drug passes into breast milk in humans, but rosuvastatin does pass into breast milk in rats.
(1) Rosuvastatin
The safety of rosuvastatin in pregnant and lactating women has not been established and should not be used during pregnancy or lactation.
Rosuvastatin is passed into rat breast milk. There are no data on transfer to breast milk in humans.
(2) Omega-3-acid ethyl ester
It is not known whether omega-3-acid ethyl ester passes into breast milk. Because many drugs are excreted in breast milk, caution should be exercised when administering to lactating women.

7. Administration to children
Safety and efficacy in children under 18 years of age have not been established.

8. Administration to elderly people
Clinical trials of this drug did not include sufficient numbers of older adults (65 years or older).
(1) Omega-3-acid ethyl ester
Only a limited number of patients over 65 years of age were included in clinical trials. A comprehensive analysis of clinical trials showed that the safety and efficacy of patients over 60 years of age (approximately 25% of the study group) were not different from the results of patients under 60 years of age.

9. Treatment in case of overdose
There is no special treatment in case of overdose. In case of overdose, symptomatic and supportive treatment should be administered. Liver function and CK levels should be monitored. Hemodialysis does not appear to help.

10. Precautions for storage and handling
1) Keep out of reach of children.
2) Be careful because changing it into another container may cause an accident or is undesirable in terms of maintaining quality.

11. Information for experts
1) Pharmacological action
(1) The mechanism of action of omega-3-acid ethyl ester has not been clearly elucidated, but it contains unsaturated fatty acids EPA and DHA, which inhibits the production of triglycerides.
(2) Rosuvastatin is an HMG-CoA reductase inhibitor and inhibits the synthesis of mevalonate, a precursor of cholesterol.
2) Pharmacokinetic information
(1) One biopharmaceutical study compared the bioavailability of this fixed-dose combination with that of the individual products taken together. In a 2 × 2 crossover study, 98 healthy adults received a single dose of rosuvastatin 20 mg and omega-3-acid ethyl esters 4 g after a meal, either as the combination or as separate products (test: four capsules of this product; reference: one Crestor 20 mg tablet and four Omacor soft capsules). Pharmacokinetic parameters were compared using plasma rosuvastatin concentrations and baseline-adjusted eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) concentrations. The 90% confidence intervals for the differences in the means of the log-transformed AUCt and Cmax values were all within log 0.8 to log 1.25, meeting the bioequivalence criteria.
(2) One comparative pharmacokinetic study was conducted to evaluate the pharmacokinetic drug interaction between rosuvastatin and omega-3-acid ethyl ester. A total of 18 healthy adults participated and took 4 capsules of this medicine, 1 20-milligram Crestor tablet, or 4 capsules of Omako soft capsule as a single dose after a meal (3 × 3 cross-over study). As a result of the test, no pharmacokinetic interaction between rosuvastatin and EPA was observed, and the AUCt of DHA was reduced to 56.64% when administered with this drug compared to when administered as a single dose of Omacor soft capsule.
(3) Although this was not a test conducted with this drug, rosuvastatin increased the median AUC and Cmax by approximately two-fold in Asians (Japan, China, Philippines, Vietnam, and Korea) compared to Caucasians. Demographic pharmacokinetic analysis showed no clinically meaningful pharmacokinetic differences between Caucasians and blacks.
3) Clinical trial information
One multicenter, randomized, double-blind, parallel group trial was conducted to evaluate the safety and efficacy of this drug in high-risk patients with coronary heart disease whose LDL-C was adequately controlled by rosuvastatin monotherapy but whose triglyceride levels were not adequately controlled.
In this clinical trial, patients underwent a 4-week introduction period of taking 20 mg of rosuvastatin before randomization. After the introduction period, patients with LDL-cholesterol appropriately controlled (less than 110 mg/dL) but high triglycerides (more than 200 mg/dL but less than 500 mg/dL) were assigned to the test group (this drug (omega-3-acid ethyl ester 1,000 mg/rosuvastatin). Patients were randomly assigned to the control group (administration of 4 capsules (5 mg)) or the control group (administration of 20 mg rosuvastatin alone). When comparing the rate of change in lipid levels after 8 weeks of administration, the rate of decrease in non-HDL-cholesterol was significantly increased in the test group compared to the control group.
The rate of change in major lipid levels after 8 weeks of administration is as follows.
See [Table 4]: Lipid levels and change rate (%) in therapeutic confirmatory clinical trials

4) Toxicity test information
(1) Repeated dose toxicity
A repeated dose toxicity test was conducted in rats in which the test substance (omega-3-acid ethyl ester: rosuvastatin 200:1) was orally administered for 13 weeks, and the administration groups were low dose group (omega-3-acid ethyl ester/rosuvastatin 250/1.25 mg/kg/day), medium dose group (omega-3-acid ethyl ester/rosuvastatin) It consisted of a high-dose group (1,000/5 mg/kg/day), a high-dose group (omega-3-acid ethyl ester/rosuvastatin 4,000/20 mg/kg/day), a rosuvastatin administration group (20 mg/kg/day), an omega-3-acid ethyl ester administration group (4,000 mg/kg/day), and a placebo control group.
Histopathological examination in the rosuvastatin administration group, the female medium-dose group, and the male and female high-dose group showed nuclear cytomegalism in hepatocytes around the portal vein, but it tended to decrease during the recovery period (NOAEL was determined to be 1,000/5 mg/kg/day for males and 250/1.25 mg/kg/day for females).
(2) Reproductive and developmental toxicity
No additional reproductive and developmental toxicity tests were conducted for the development of the combination drug.
The known reproductive and developmental toxicity for each single agent is as follows.
① Rosuvastatin: In pre- and postnatal developmental tests in rats, reproductive toxicity was observed, including reduced litter size, reduced litter weight, and decreased survival of the next generation. This effect was observed when a dose equivalent to several times the therapeutic dose was administered systemically to the mother.
② Omega-3-acid ethyl ester: When a dose 7 times the recommended human dose of 4 g/day based on body surface area was administered to pregnant rats, embryonic death was observed.
- When doses of 100, 600, and 2000 mg/kg/day were administered orally to rats from the 14th day of pregnancy to the 21st day of lactation, no adverse reactions were observed at 2000 mg/kg/day. However, at a higher dose of 3000 mg/kg/day (7 times the total body exposure oral dose of 4g/day based on body surface area), the number of live births decreased by 20%, and the survival rate decreased by 40% until 4 days after birth.
- Rabbits received oral doses of 375, 750, or 1500 mg/kg/day from gestation days 7 to 19. These doses correspond to 2, 4, and 8 times the human oral dose of 4 g/day, respectively, based on body surface area. No fetal effects were observed at 375 mg/kg/day. However, evidence of maternal toxicity was observed at higher doses.

5. How to save
Airtight container, stored at room temperature (1~30℃)

6. Packaging unit
100 capsules/box (10 capsules/PTP×10)

7. Period of use
36 months from date of manufacture

Product Updates

Total 6items

No.Product NameDetailsDate of ChangeDownload
6Megarovan Soft Cap. 5/1000mgPrecautions for use2025.03.06PDF0007_202008416_Megaro semi-soft capsule 5/1000mg_Precautions for use (draft change).pdf
5Megarovan Soft Cap. 5/1000mgPrecautions for use2024.09.036. Megaroban soft capsule 5/1000mg_Precautions for use Change order (draft) and change comparison table.pdfFile under review
4Megarovan Soft Cap. 5/1000mgPrecautions for use2024.04.23PDFMegaroban soft capsule 5│1000mg_Permission change order (draft) (precautions for use).pdf
3Megarovan Soft Cap. 5/1000mgPrecautions for use2024.04.16Megaroban soft capsule change order (draft)_Change comparison table added.pdfFile under review
2Megarovan Soft Cap. 5/1000mgPrecautions for use2023.04.06PDF0848_202008416_Precautions for use_Megaro semi-soft capsule 5/1000mg (including change comparison table).pdf
1Megarovan Soft Cap. 5/1000mgPrecautions for use2022.01.25PDFMegaroban soft capsule 5_1000mg change plan (final).pdf